| Name | 3-(6-ethanesulfonylpyridin-3-yloxy)-5-((S)-2-hydroxy-1-methylethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide methanesulfonic acid salt |
|---|---|
| Synonyms |
3-(6-ethanesulfonylpyridin-3-yloxy)-5-((1S)-2-hydroxy-1-methyl-ethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide methanesulfonate
MK-0941 |
| Description | MK-0941 is a potent, orally active and allosteric glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 has potential in the treatment of type 2 diabetes[1]. |
|---|---|
| Related Catalog | |
| Target |
EC50: 240 nM (Recombinant human glucokinase, 2.5 mM glucose), 65 nM (Recombinant human glucokinase, 10 mM glucose)[1] |
| References |
| Molecular Formula | C22H28N4O9S2 |
|---|---|
| Molecular Weight | 556.60900 |
| Exact Mass | 556.13000 |
| PSA | 203.77000 |
| LogP | 4.15150 |
| Storage condition | -20℃ |